Medical technology company AngioDynamics Inc (NASDAQ:ANGO) announced on Wednesday that it has initiated a global study to assess the long-term effects of its NanoKnife System in treating prostate cancer.

Conducted in partnership with University College London Hospital (UCLH), the study aims to validate the safety and efficacy of the NanoKnife System, which offers a less invasive alternative to traditional treatments.

By preserving vital structures inside and outside the prostate, the NanoKnife System seeks to minimise complications and improve patient quality of life.